ClinicalTrials.Veeva

Menu

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women

University of Colorado Denver (CU Denver) logo

University of Colorado Denver (CU Denver)

Status

Begins enrollment in 2 months

Conditions

Breast Cancer Female

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT06441474
23-0345.cc
1R01CA279953-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal observational study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.

Full description

The Understanding and Addressing Rejection of Personalized Cancer Risk Information study seeks to understand the nature of the phenomenon of personalized cancer risk rejection in the context of mammography screening by 1) identifying demographic and psychological factors associated with risk rejection and 2) identify how risk rejection influences risk-concordant mammography seeking behavior. The study will test a priori theory-derived hypotheses about the precursors of risk rejection and the influence of rejection on real-life screening decision making.

The Breast Cancer Risk Assessment Tool (BCRAT) will be used to asses participant's breast cancer risk. This model is designed to estimate breast cancer risk in women 35-84, and uses the following predictors: 1) age, 2) age at first menstrual period, 3) age at first live birth, 4) first-degree relatives with breast cancer, 5) previous breast biopsy with atypical hyperplasia, and 6) race/ethnicity Participants will be required to complete the baseline survey in which they receive their Gail model risk estimate and respond to that risk estimate. They will then complete a 12-month follow-up survey.

Enrollment

750 estimated patients

Sex

Female

Ages

39 to 49 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Female sex
  2. Age 39-49 (i.e., people who are eligible for routine breast cancer screening and for whom guidelines recommend an informed, risk-based decision)
  3. English literacy

Exclusion criteria

  1. Prior diagnosis of

  2. breast cancer

  3. Ductal carcinoma in situ (DCIS)

  4. Lobular carcinoma in situ (LCIS)

  5. Known BRCA1/2 gene mutation

  6. Cowan syndrome

  7. Li-Fraumeni syndrome

  8. Having received previous chest radiation for treatment of Hodgkin's lymphoma.

Trial contacts and locations

2

Loading...

Central trial contact

Michelle Eggers; Damilola Jolaoso, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems